Key facts
- It has raised $10K; the latest was Later Stage VC in Jul 2025.
- Notable investors include Venture Kick, Kickfund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Shape Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Shape Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shape Biopharmaceuticals
Developer of immunotherapeutic drugs designed to focus on treating chronic diseases with limited treatment options. The company develops advanced protein design and formulation technologies, aiming to create a new generation of immunotherapies that can address unmet needs and improve patient outcomes, enabling laboratories to offer hope for individuals with genetically driven conditions who have limited therapeutic options with the technology.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Website
- shapebiopharma.com/
- Ownership
- Privately Held (backing)
Shape Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shape Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shape Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.